ABOS - Company ID 0001576885
The table below shows Acumen Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$24.13M | -$34.12M | -$17.86M | -$10.18M | -$8.30M | -$2.37M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | -$13.81M | $28.69M | -$9.20M | -$41.93M | -$5.10M | - |
| Dividends paid | - | - | - | - |
Acumen Pharmaceuticals, Inc. reported operating cash flow of -$115.54M for fiscal year 2025. That is down 34.0% from -$86.22M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$7.45M (FY 2020) to -$115.54M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $35.74M | -$36.00K | $7.11M | $0.00 | - | - |